Results 101 to 110 of about 36,246 (163)

Exploring the pharmacological mechanisms of resibufogenin in castration-resistant prostate cancer via network pharmacology and experimental validation. [PDF]

Front Oncol
Xing Y, Xiang L, Jia Y, Yang Y.
europepmc   +1 more source

Phase II Trial of Opaganib Addition in Metastatic Castration-Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide. [PDF]

Cancer Med
Brown JT, Nazha B, Ferreira AC, Armeson K, Hill EG, Ogretmen B, Mehrotra S, Brisendine A, Magrath G, Plasse TF, Gourdin TS, Kucuk O, Lilly M.   +12 more
europepmc   +1 more source

The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer. [PDF]

Cancer Res
Kittane S, Ladewig E, Li T, Love JR, Blawski R, Gao Y, Arruabarrena-Aristorena A, Zhao P, Dalrymple SL, Liu H, Guo X, Sallaku M, Kelkar N, Garcia-Martinez L, Carmona Sanz J, Chen W, Stoudmann C, Baldino L, Razavi-Mohseni M, Kalemi I, Beer MA, Castel P, Brennen WN, Scaltriti M, Morey L, Cocco E, Ji H, Chan HM, Battle A, Leslie CS, Karthaus WR, Toska E.   +31 more
europepmc   +1 more source

Two Cases of Metastatic Castration-Resistant Prostate Cancer With Long-Term Survival Treated With Abiraterone. [PDF]

Clin Case Rep
Une M, Yamamoto S, Fuse H, Fujiwara R, Yonese J, Noda K.   +5 more
europepmc   +1 more source

HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer. [PDF]

Cell Death Dis
Yanushko D, Pichot A, Vincent A, Keime C, Laverny G, Metzger D.   +5 more
europepmc   +1 more source

Correction: SLC7A11 upregulation via AR and NEDD4L ubiquitination contributes to ferroptosis inhibition and enzalutamide resistance in castration-resistant prostate cancer. [PDF]

Cell Death Dis
Tang M, Xue L, Wang B, Jiang Z, Li P, Bu H, Zhao C, Zhang Y, Liu S, Chen X, Liu B, Meng X, Li J.   +12 more
europepmc   +1 more source

Molecular insights into DDX3X-androgen receptor mRNA regulation via non-canonical G-quadruplex in castration-resistant prostate cancer. [PDF]

Oncogene
Zhang H, Liu TT, Wu F, Colah AN, Ricke EA, Li L, Putnam AA, Ricke WA.   +7 more
europepmc   +1 more source

Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration-Resistant Prostate Cancer. [PDF]

Prostate
Kawai T, Maki K, Taguchi S, Fujii Y, Tanaka T, Miyakawa J, Kamei J, Kakutani S, Niimi A, Yamada D, Yamada Y, Takada T, Nakagawa T, Kume H.   +13 more
europepmc   +1 more source

Visceral and subcutaneous fat attenuation as prognostic indicators of survival in castration resistant prostate cancer. [PDF]

Prostate Int
Heo JE, Han HH, Jang WS, Lee SH, Ham WS, Han WK, Choi YD, Lee J.   +7 more
europepmc   +1 more source